Related Experiment Video
Updated: May 9, 2026

Spectral Confocal Imaging of Fluorescently tagged Nicotinic Receptors in Knock-in Mice with Chronic Nicotine Administration
Published on: February 10, 2012
[The nicotine receptor as target for the improvement of cognitive symptoms in schizophrenia]
C Quisenaerts1, M Morrens, B Sabbe
1Universiteit van Antwerpen, 2610 Wilrijk, België. charelq@hotmail.com
Background:
Nicotine receptor agonists are drugs that may be useful for the treatment of cognitive symptoms in schizophrenia.
Aim:
By studying the relevant literature we want to investigate to what extent nicotine enhances cognition in patients with schizophrenia and to find out which domains are affected. We also attempt to identify the obstacles that might impede the use, in the future, of nicotine receptor agonists. In addition, we aim to present the most likely neurobiological working mechanism of nicotine.
Method:
We searched the literature using PubMed and the search terms ‘schizophrenia’, (‘nicotine’ or ‘smoking’), ‘cognition’ and ‘P50’.
Results:
Attention and visuo-spatial memory seems to respond favourably to once-only stimulation by nicotine. These results are supported both by the improvement that nicotine brought about in the signal-to-noise ratio in a P50 sensory grating paradigm and by the neurobiological findings. However, the effect of chronic nicotinergic stimulation is less clear.
Conclusion:
There is some evidence that nicotine does have a mild but acute cognition-enhancing effect in patients with schizophrenia. However, nicotine is not suitable for clinical use, because it can have side effects and lead to addiction and desensitisation of the nicotine receptor. Nevertheless, nicotine receptor agonists do have the potential to enhance and stimulate cognition.
Related Concept Videos
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
CNS Depressants: Alcohol and Nicotine
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...
Cholinergic Receptors: Nicotinic
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
Psychosis: Goals of Pharmacotherapy